Indeed, Galectin-3 is suggested as an immunotherapeutic target improving the outcome of inhibitory checkpoint inhibition in cancer immunotherapy, were Galectin-3 inhibition for example was demonstrated to augment the PD-L1 response in a mouse model of lung adenocarcinoma (89, 90). Here, LGALS3 is linked to cancer.